Watching a short video before anti-VEGF eye injections
Official title: Impact of Procedural Video Viewing on Patients Undergoing Intravitreal Anti-VEGF Injections
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07002372 · Data updated 2026-11-12
This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 182 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | May 5, 2025 |
| Main results expected | August 5, 2025 |
| Study ends | October 5, 2025 |
| Registry record updated | June 3, 2025 |
| Trial ID | NCT07002372 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are mentally competent adults receiving their first intravitreal anti-VEGF injection for retinal disease who can communicate without barriers and are willing to sign informed consent.
✕Probably not a fit
Patients with prior eye surgery, a best-corrected visual acuity in the better eye worse than 0.3, or a target eye complicated by neovascular glaucoma are excluded and unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults receiving their first intravitreal anti-VEGF injection for retinal disease are randomly assigned to watch an educational video explaining the injection procedure or to receive standard care without the video. Anxiety is measured with the State-Trait Anxiety Inventory-State (STAI-S) before and after the injection, and clinicians record the presence and area of subconjunctival hemorrhage after the procedure. Patient satisfaction and immediate procedural experience are also collected. The trial is conducted at the Second Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China.
Why it matters
Potential benefit: If successful, the video could reduce procedure-related anxiety and decrease the frequency or size of subconjunctival hemorrhages, improving patient comfort and satisfaction.
How similar studies have gone: Video-based and other preprocedure education have reduced anxiety and increased satisfaction in other medical and ophthalmic settings, but direct evidence specific to intravitreal injections is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are receiving their first intravitreal injection of anti-VEGF medication due to retinal diseases * Mentally competent, and able to communicate without barriers * Willing to voluntarily sign an informed consent form. Exclusion Criteria: * History of previous eye surgery * Best-corrected visual acuity in the better eye worse than 0.3 * The target eye is complicated with neovascular glaucoma.
Where it's running
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Xiaoyun Fang, MD., PhD — Second Affiliated Hospital, Zhejiang University, School of Medicine
- Study coordinator: Xiaoyun Fang, MD., PhD.
- Email: xiaoyunfang@zju.edu.cn
- Phone: + 86 13588411946
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biorepository for studying retinal diseases
This study is collecting health information and samples from people with and without eye diseases to see how these conditions develop and respond to treatments.
-
Hyperspectral imaging to map retinal and optic nerve structures
This study will test whether hyperspectral retinal imaging can detect disease-related features in adults with diabetic retinopathy, glaucoma, age-related macular degeneration, and in healthy volunteers.
-
Tiespectus (MK-8748) versus aflibercept to treat neovascular (wet) age-related macular degeneration
The study will see if tiespectus (MK-8748) works as well as aflibercept for people with newly diagnosed neovascular (wet) age-related macular degeneration.
-
Comparing tiespectus (MK-8748) with aflibercept for wet age-related macular degeneration
This study will test whether tiespectus (MK-8748) works as well as aflibercept for people with newly diagnosed neovascular (wet) age-related macular degeneration.
-
High Resolution Imaging OCT Study
This study tests whether two investigational OCT devices (R1 and HighRes OCT) produce better image quality than the standard Spectralis in adults with normal eyes or with AMD, diabetic retinopathy, or other retinal diseases.
-
Vision screening in general practice to catch preventable sight loss in people over 70
This project will test a GP-based vision-screening program for people aged 70 and older with at least one chronic condition to find sight problems early.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.